-
Our medicinal chemists believe that 'every compound counts' - Dr Trevor Perrior, CEOEvery Compound Counts -
Domainex is committed to the support of exciting and cutting-edge translational researchTranslational Research -
Domainex applies unique technologies to overcome common drug discovery challengesOvercome Challenges -
Domainex is developing an exciting pipeline of drugs that effect epigenetic targetsExciting Pipeline
Drug Discovery Services
Domainex is the fastest growing CRO in Europe. By applying our novel proprietary technologies such as CDH and taking a focussed, integrated approach to medicinal chemistry, biochemistry and computational chemistry we can reduce your project timeline by up to 30%.
New technologies
Domainex has received an award of £118,000 from the UK’s innovation agency, Innovate UK, to develop a new biophysical screening method for G-protein coupled receptors (GPCRs). Here's a short video explaining how the technology works. GPCRs video.
Technology
FragmentBuilder: Fragment screening using MicroScale Thermophoresis
Combinatorial Domain Hunting: Protein expression and purification services.
BioassayBuilder: Bioassay services, assay development, HTS and compound testing services.
LeadBuilder: Virtual hit screening platform.